These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 22532316

  • 1. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.
    Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
    [Abstract] [Full Text] [Related]

  • 2. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 3. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
    Simon P, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, Bercker S.
    World J Gastroenterol; 2016 Mar 28; 22(12):3412-7. PubMed ID: 27022223
    [Abstract] [Full Text] [Related]

  • 4. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.
    Liver Transpl; 2007 Dec 28; 13(12):1703-9. PubMed ID: 18044717
    [Abstract] [Full Text] [Related]

  • 5. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 6. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L, Helou S, Bachelet T, Martin S, Moreau K, Morel D, Lafon ME, Garrigue I, Merville P.
    Transplant Proc; 2012 Nov 27; 44(9):2809-13. PubMed ID: 23146529
    [Abstract] [Full Text] [Related]

  • 7. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 27; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 8. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2008 Feb 27; 14(2):240-4. PubMed ID: 18236404
    [Abstract] [Full Text] [Related]

  • 9. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
    Fayek SA, Mantipisitkul W, Rasetto F, Munivenkatappa R, Barth RN, Philosophe B.
    HPB (Oxford); 2010 Dec 27; 12(10):657-63. PubMed ID: 21083790
    [Abstract] [Full Text] [Related]

  • 10. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP.
    JAMA; 2020 Apr 14; 323(14):1378-1387. PubMed ID: 32286644
    [Abstract] [Full Text] [Related]

  • 11. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Apr 14; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 12. Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.
    Scott GM, Naing Z, Pavlovic J, Iwasenko JM, Angus P, Jones R, Rawlinson WD.
    J Clin Virol; 2011 Aug 14; 51(4):229-33. PubMed ID: 21641274
    [Abstract] [Full Text] [Related]

  • 13. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT, Tsapepas DS, Li H, Anamisis A, Martin ST.
    Prog Transplant; 2015 Mar 14; 25(1):39-44. PubMed ID: 25758799
    [Abstract] [Full Text] [Related]

  • 14. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S, Sullivan T, Ali M, Dunn D, Patel G, Huprikar S.
    Liver Transpl; 2018 May 14; 24(5):616-622. PubMed ID: 29500912
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR.
    World J Gastroenterol; 2008 Aug 21; 14(31):4849-60. PubMed ID: 18756591
    [Abstract] [Full Text] [Related]

  • 16. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 21; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus Treatment Strategy After a Liver Transplant: Preemptive Therapy or Prophylaxis for Cytomegalovirus Seropositive Donor and Recipient.
    Lindner K, Anthoni C, Beckebaum S, Senninger N, Hölzen JP, Wolters H.
    Exp Clin Transplant; 2016 Aug 21; 14(4):419-23. PubMed ID: 27506260
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 21; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA.
    Transplantation; 2015 Jul 21; 99(7):1499-505. PubMed ID: 25643140
    [Abstract] [Full Text] [Related]

  • 20. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I.
    J Med Virol; 2013 May 21; 85(5):893-8. PubMed ID: 23508914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.